Skip to Main Content

++

INTRODUCTION

++

balsalazide (ba-sal-a-zide)

Colazal

Classification

Therapeutic: gastrointestinal anti-inflammatories—therapeutic

Pharmacologic: salicylates

++
Indications
++

Treatment of mild-to-moderately active ulcerative colitis.

++
Action
++

Drug is metabolized in the colon to mesalamine (5-aminosalicylic acid), which is a local anti-inflammatory. Therapeutic Effects: Reduction in the symptoms of ulcerative colitis.

++
Adverse Reactions/Side Effects
++

GI: HEPATOTOXICITY, abdominal pain, diarrhea.

++

PHYSICAL THERAPY IMPLICATIONS

++
Examination and Evaluation
++

  • Be alert for signs of hepatotoxicity, including anorexia, abdominal pain, severe nausea and vomiting, yellow skin or eyes, fever, sore throat, malaise, weakness, facial edema, lethargy, and unusual bleeding or bruising. Notify physician of these signs immediately.

++
Patient/Client-Related Instruction
++

  • Advise patient to avoid alcohol and foods that may cause an increase in GI irritation.

  • Instruct patient to report troublesome GI effects such as diarrhea and abdominal pain.

++
Pharmacokinetics
++

Absorption: Absorption is low and variable; drug is delivered intact to the colon.

++

Distribution: Mostly delivered intact to the colon; remainder of distribution unknown.

++

Protein Binding: ≥99%.

++

Metabolism and Excretion: Following delivery to the colon, bacteria break balsalazide down into mesalamine (5-aminosalicylic acid) and an inactive metabolite; mostly excreted in feces.

++

Half-life: Mesalamine—12 hr (range 2–15 hr).

++

Table Graphic Jump Location
Favorite Table | Download (.pdf) | Print

TIME/ACTION PROFILE (decreased symptoms)

ROUTE ONSET PEAK DURATION
PO unknown up to 8 wk unknown

++
Contraindications/Precautions
++

Contraindicated in: Hypersensitivity to salicylates or other metabolites.

++

Use Cautiously in: Pyloric stenosis (may have prolonged gastric retention of capsules); OB: Use only if clearly needed; Lactation/Pedi: Safety not established.

++
Interactions
++

Drug-Drug: None known.

++
Route/Dosage
++

PO (Adults): 3 750-mg capsules 3 times daily for 8–12 wk.

++

PO (Children 5–17 yr): 3 750-mg capsules 3 times daily for up to 8 wk or 1 750-mg capsule 3 times daily for up to 8 wk.

++
Availability
++

Capsules: 750 mg.

Want remote access to your institution's subscription?

Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.

Ok

About MyAccess

If your institution subscribes to this resource, and you don't have a MyAccess profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.